Opendata, web and dolomites

ARTimmune SIGNED

Programmable ARTificial immune systems to fight cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ARTimmune project word cloud

Explore the words cloud of the ARTimmune project. It provides you a very rough idea of what is the project "ARTimmune" about.

molecules    immunomodulators    powerhouses    life    proteolytic    roadblocks    vicinity    generate    revolutionary    vaccinated    destruction    moving    cytotoxic    decorated    blueprint    programming    branched    immunotherapies    hypothesize    character    systemic    maximal    entered    innovative    transcriptomics    vivo    bursts    porosity    span    cells    illustrate    follow    chemical    advantage    direct    extend    scaffolds    cell    node    activation    clusters    accomplished    infiltration    communication    intelligent    powerful    immune    toxic    function    dose    obstacles    architecture    mixed    treatment    ln    mimic    locally    act    fundamental    immunotherapy    injected    local    tolerable    centre    stage    programmable    tuning    tumour    immunosuppression    successful    lymph    artimmune    structures    immunological    fine    notwithstanding    cancer    synthetic    overcome    immunomodulating    injectable    patients    revolutionize    tools    pressing    polymeric    radically    niches    toxicity    sponge    single    modality    instruct   

Project "ARTimmune" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-ADG
 Funding Scheme ERC-ADG
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2024-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 2˙500˙000.00

Map

 Project objective

Immunotherapy has entered centre stage as a novel treatment modality for cancer. Notwithstanding this major step forward, toxicity and immunosuppression remain major obstacles, and illustrate the pressing need for more powerful and specific immunotherapies against cancer. To overcome these roadblocks, in ARTimmune, I propose to follow a radically different approach by developing local rather than systemic immunotherapies. Taking advantage of the architecture of a lymph node (LN), I aim to design fully synthetic immune niches to locally instruct immune cell function. I hypothesize that programmable synthetic immune niches, when injected next to a tumour, will act as local powerhouses to generate bursts of cytotoxic T cells for tumour destruction, without toxic side effects. Single cell transcriptomics on LN, obtained from patients that are vaccinated against cancer, will provide unique insight in communication within immune cell clusters and provide a blueprint for the intelligent design of synthetic immune niches. Chemical tools will be used to build branched polymeric structures decorated with immunomodulating molecules to mimic LN architecture. These will be injected, mixed with sponge-like scaffolds to provide porosity needed for immune cell infiltration. Programming of immune cell function will be accomplished by in vivo targeting- and proteolytic activation- of immunomodulators for fine-tuning, and to extend the life span of these local powerhouses. The innovative character of ARTimmune comes from: 1) novel fundamental immunological insight in complex communication within LN cell clusters, 2) a revolutionary new approach in immunotherapy, by the development of 3) injectable- and 4) programmable- synthetic immune niches by state-of-the-art chemical technology. When successful, it will revolutionize cancer immunotherapy, moving from maximal tolerable dose systemic treatment with significant toxicity to local low dose treatment in the direct vicinity of a tumour

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ARTIMMUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ARTIMMUNE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

KineTic (2020)

New Reagents for Quantifying the Routing and Kinetics of T-cell Activation

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More  

NEUTRAMENTH (2018)

A redox-neutral process for the cost-efficient and environmentally friendly production of Menthol

Read More